Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology (Nasdaq: KURA) announced FDA clearance of an IND application for ziftomenib, their menin inhibitor, to treat advanced gastrointestinal stromal tumors (GIST). A Phase 1 study combining ziftomenib with imatinib is planned for early 2025. Preclinical data suggest this combination could resensitize patients to imatinib and induce durable responses in imatinib-resistant cases. GIST, the most common sarcoma, is typically treated with KIT inhibitors like imatinib. However, many patients develop resistance, limiting treatment options. Ziftomenib targets the menin-MLL complex, which regulates KIT expression in GIST cells. This marks the first IND clearance for a menin inhibitor in GIST treatment, potentially offering a new approach for patients with options.
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. financial markets close. The company's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and provide a corporate update.
Interested parties can access the live call by dialing (877) 300-8521 (domestic) or (412) 317-6026 (international). A live webcast and archived replay of the event will be available on the company's website at www.kuraoncology.com in the investor relations section.
Kura Oncology, a clinical-stage biopharmaceutical company, announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4) on July 1, 2024. The Compensation Committee granted nonstatutory stock options to purchase 128,700 shares of common stock to eight new employees under the 2023 Inducement Option Plan. These options have an exercise price of $21.20 per share, matching the closing sales price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder monthly over the following 36 months, subject to continuous service.
Kura Oncology has presented preclinical data showing the potential of menin inhibitors, specifically ziftomenib, in treating type 2 diabetes. The findings, shared at the American Diabetes Association’s 84th Scientific Sessions, highlight ziftomenib's ability to enhance pancreatic function, boost insulin production, and improve insulin sensitivity in preclinical models. Notably, the therapeutic effects persisted even after stopping the dose, indicating a possible restoration of beta-cell mass. Kura is also developing next-generation menin inhibitors targeting diabetes and other metabolic diseases, in addition to its ongoing clinical trials in acute leukemias.
Kura Oncology announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4). On June 3, 2024, the Compensation Committee awarded nonstatutory stock options to purchase 152,500 shares of common stock to eight new employees under the 2023 Inducement Option Plan. The exercise price for each option is $21.19 per share, matching the closing sales price on the grant date. The options vest over four years—25% after one year and the remainder monthly over the next 36 months, contingent on continued employment. These inducement awards aim to attract and retain talent effectively.
Kura Oncology, a clinical-stage biopharmaceutical company, has announced its participation in the Jefferies Global Healthcare Conference.
Troy Wilson, President and CEO, will engage in a virtual fireside chat on June 5, 2024, at 3:00 p.m. ET / 12:00 p.m. PT.
A live audio webcast and an archived replay will be accessible in the Investors section of Kura's website.
Kura Oncology has completed enrollment of 85 patients in its Phase 2 KOMET-001 clinical trial, targeting relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML), within 16 months.
The trial focuses on assessing the clinical activity, safety, and tolerability of their menin inhibitor, ziftomenib (KO-539). Topline data is expected in early 2025.
Notably, ziftomenib has received Breakthrough Therapy Designation from the FDA, which aims to expedite the review process for new drug applications due to its potential efficacy in treating R/R NPM1-mutant AML.
This milestone underscores the urgent need for effective treatment options in AML and highlights ziftomenib's potential to become a best-in-class treatment.
Kura Oncology, Inc. (Nasdaq: KURA) will participate in Bank of America Securities 2024 Healthcare Conference, with the company's President and CEO scheduled for a virtual fireside chat. The event will take place on May 15, 2024, providing investors with insights into the company's progress and future prospects.
Kura Oncology, Inc. announced the granting of inducement awards in the form of nonstatutory stock options to six new employees under the 2023 Inducement Option Plan. The stock options will allow the purchase of 67,950 shares of common stock at an exercise price of $20.28 per share. The options will vest over four years, with 25% vesting after one year, and the rest vesting monthly over 36 months, contingent on the employees' continued service relationship.
Kura Oncology reported first quarter 2024 financial results, highlighting Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML, positive preliminary combination data, and first patient dosing with KO-2806 and cabozantinib. The company has $527 million in cash, cash equivalents, and investments, ensuring runway into 2027. Financially, research and development expenses increased to $36.3 million, while general and administrative expenses rose to $18.2 million. The net loss for Q1 2024 was $49.5 million. Management expects current funds to last into 2027.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
